title: Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia.
abstract: Pharmacokinetic-pharmacodynamic (PK-PD) analyses for efficacy using phase III trial data from patients treated with a ceftaroline fosamil dosing regimen of 600 mg intravenously (i.v.) every 12 h (q12h) for 5 to 7 days for community-acquired bacterial pneumonia (CABP) were conducted. High clinical and microbiological success rates (84.7 and 86.3%, respectively) and percentages of time during the dosing interval that free-drug steady-state concentrations remained above the MIC (f%T>MIC) (98.4% had f%T>MIC values of ≥63.3) were observed among 124 microbiologically evaluable patients. As a result, significant PK-PD relationships could not be identified. These data provide support for the use of a ceftaroline fosamil dosing regimen of 600 mg i.v. q12h to treat patients with CABP.
authors.affiliation: Institute for Clinical Pharmacodynamics, Latham, New York, USA.
authors.forename: Sujata M
authors.initials: SM
authors.lastname: Bhavnani
authors.forename: Jeffrey P
authors.initials: JP
authors.lastname: Hammel
authors.forename: Scott A
authors.initials: SA
authors.lastname: Van Wart
authors.forename: Christopher M
authors.initials: CM
authors.lastname: Rubino
authors.forename: Daniel K
authors.initials: DK
authors.lastname: Reynolds
authors.forename: Alan
authors.initials: A
authors.lastname: Forrest
authors.forename: Tatiana
authors.initials: T
authors.lastname: Khariton
authors.forename: H David
authors.initials: HD
authors.lastname: Friedland
authors.forename: Todd A
authors.initials: TA
authors.lastname: Riccobene
authors.forename: Paul G
authors.initials: PG
authors.lastname: Ambrose
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000900:Anti-Bacterial Agents / Q000097:blood / Q000493:pharmacokinetics* / Q000627:therapeutic use; D002511:Cephalosporins / Q000097:blood* / Q000493:pharmacokinetics* / Q000627:therapeutic use; D017714:Community-Acquired Infections / Q000097:blood / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011014:Pneumonia / Q000097:blood / Q000188:drug therapy; D055815:Young Adult; D000097583:Ceftaroline
chemical_list: D000900:Anti-Bacterial Agents; D002511:Cephalosporins; D000097583:Ceftaroline
references.citation: J Antimicrob Chemother. 2002 Sep;50(3):425-8
references.pmid: 12205070
references.citation: J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii33-44
references.pmid: 21482568
references.citation: J Clin Pharmacol. 2013 Nov;53(11):1155-67
references.pmid: 23907740
references.citation: Antimicrob Agents Chemother. 2006 Apr;50(4):1376-83
references.pmid: 16569855
references.citation: J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii19-32
references.pmid: 21482566
references.citation: J Pharmacokinet Biopharm. 1981 Aug;9(4):503-12
references.pmid: 7310648
references.citation: Antimicrob Agents Chemother. 2015 Jan;59(1):372-80
references.pmid: 25367904
references.citation: J Bacteriol. 1947 Jul;54(1):6
references.pmid: 20255102
references.citation: J Antimicrob Chemother. 2011 Apr;66 Suppl 3:iii11-8
references.pmid: 21482565